
Quanterix Corp — Investor Relations & Filings
Quanterix Corporation is a company focused on digitizing biomarker analysis to advance the science of precision health. Its core offering is the proprietary Simoa® technology, an ultra-sensitive digital immunoassay platform designed to detect and measure biomarkers at extremely low concentrations. This capability allows researchers to study the biology of health and disease with high precision, enabling earlier disease detection, improved prognoses, and the development of more effective treatment methods. The Simoa platform is utilized across a wide range of therapeutic areas, including a strategic focus on neurology (neurodegeneration, neuroinflammation, traumatic brain injuries), as well as oncology, cardiology, inflammation, and infectious diseases.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - Quanterix Corp (0001503274) (Filer) | 2026-05-06 | English | |
| ARS - Quanterix Corp (0001503274) (Filer) | 2026-04-24 | English | |
| DEF 14A - Quanterix Corp (0001503274) (Filer) | 2026-04-24 | English | |
| 3 - Quanterix Corp (0001503274) (Issuer) | 2026-03-24 | English | |
| 4 - Quanterix Corp (0001503274) (Issuer) | 2026-03-17 | English | |
| 3 - Quanterix Corp (0001503274) (Issuer) | 2026-03-17 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 41998200 | 8-K - Quanterix Corp (0001503274) (Filer) | 2026-05-06 | English | ||
| 36127788 | ARS - Quanterix Corp (0001503274) (Filer) | 2026-04-24 | English | ||
| 36127820 | DEF 14A - Quanterix Corp (0001503274) (Filer) | 2026-04-24 | English | ||
| 33034998 | 3 - Quanterix Corp (0001503274) (Issuer) | 2026-03-24 | English | ||
| 32968563 | 4 - Quanterix Corp (0001503274) (Issuer) | 2026-03-17 | English | ||
| 32968562 | 3 - Quanterix Corp (0001503274) (Issuer) | 2026-03-17 | English | ||
| 32892834 | 10-K - QUANTERIX CORP (0001503274) (Filer) | 2026-03-02 | English | ||
| 32892833 | 8-K - QUANTERIX CORP (0001503274) (Filer) | 2026-03-02 | English | ||
| 32892832 | 4 - QUANTERIX CORP (0001503274) (Filer) | 2026-02-18 | English | ||
| 30191110 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 30191109 | 4 Filing | 2026-02-06 | English | ||
| 30191105 | 4 Filing | 2026-01-21 | English | ||
| 30191104 | 3 Filing | 2026-01-21 | English | ||
| 30191111 | 4 Filing | 2026-01-20 | English | ||
| 30191086 | 4 Filing | 2026-01-20 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Aptose Biosciences Inc.
Clinical-stage company developing targeted precision medici…
|
APS | CA | Professional, scientific and te… |
|
APURES CO., LTD.
Biotech firm providing MICROPIG models, bio-resources, and …
|
149300 | KR | Professional, scientific and te… |
|
Aran Research & Development (1982) Ltd.
A product design and development firm providing services fr…
|
ARAN | IL | Professional, scientific and te… |
|
Arch Biopartners Inc.
Developing novel drugs for acute kidney injury (AKI) and ch…
|
ARCH | CA | Professional, scientific and te… |
|
ARCHER MATERIALS LIMITED
Develops semiconductor devices for quantum computing and me…
|
AXE | AU | Professional, scientific and te… |
|
ARGENICA THERAPEUTICS LIMITED
Clinical-stage developer of neuroprotective drugs for acute…
|
AGN | AU | Professional, scientific and te… |
|
ARIUS Research Inc.
Discovery and development of targeted antibody therapeutics…
|
ARI | CA | Professional, scientific and te… |
|
AROVELLA THERAPEUTICS LIMITED
Develops off-the-shelf iNKT cell therapies for blood cancer…
|
ALA | AU | Professional, scientific and te… |
|
Artiva Biotherapeutics, Inc.
Develops allogeneic, off-the-shelf NK cell therapies for ca…
|
ARTV | US | Professional, scientific and te… |
|
ARVINAS, INC.
Clinical-stage biopharma developing therapeutics based on t…
|
ARVN | US | Professional, scientific and te… |
Quanterix Corp via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33531/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33531 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33531 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33531 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33531}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Quanterix Corp (id: 33531)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.